Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities

Stopped early · Not applicable · Has a placebo group

Conditions studied: Peripheral Arterial Disease

In brief

The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. Investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. Lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication.

Key facts

Study ID

NCT00914316

Run by

Corewell Health East

People needed

29

Starts

2009-05-01

Expected to finish

2013-03-01

Last updated by the study team

2017-08-09

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females greater than 40 years of age.
• Documented peripheral arterial disease
• Stable lower extremity intermittent claudication (Rutherford class 1-3) for 3 months.

You may not qualify if…

• Critical limb ischemia (Rutherford class 4-6).
• Percutaneous or surgical lower extremity revascularization within last 12 months.
• Myocardial infarction within the last 6 months.
• cardiac surgery within the last 6 months.
• Unstable angina
• Stable chronic angina
• New York Heart Association Class II-IV heart failure
• Left ventricular ejection fraction less than or equal to 35%
• Venous thromboembolism within the last 6 months.
• Uncontrolled high blood pressure, defined as systolic blood pressure greater than or equal to 180 mmHg or diastolic blood pressure greater than or equal to 110 mmHg.
• Allergy to ranolazine.
• corrected QT interval (QTc) greater than or equal to 440 ms in males or 460 ms in females.
• Pregnant or nursing females.
• Chronic dialysis therapy.
• Significant liver impairment (defined as transaminases greater than or equal to 3 times the upper limit of normal) within the last 6 months.
• Concomitant use of Cytochrome P450-3A (CYP3A) inhibitors
• Concomitant use of CYP3A inducers
• QTc prolonging agents
• Orthopedic or neurologic disorders that prevent treadmill walking.
• Current participation in a structured exercise program.

Where it is running

• William Beaumont Hospital — Royal Oak, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.